Objective: To investigate the effects of ST7L on the proliferation, cell cycle and tumor xenograft of ovarian cancer. Methods: Ectopic expression plasmid of ST7L by PCR and compounded the knockdown plasmid were established. ST7L was over-expressed and knocked down in OVCAR3 and SKOV3 cells via lipidosome 2000 transfection. Fluorescence based quantitative polymerase chain reaction and western blot assay were used to analyze the expression of ST7L. MTT, colony formation assay and flow cytometry were applied to detect the effects of ST7L on the proliferation and cell cycle of OVCAR3 and SKOV3 cells after transfection. Tumor xenograft studies were used to observe the tumor growth in vivo. Results: The used plasmids were effective; the ectopic expression of ST7L suppressed the proliferation and cell cycle of OVCAR3 and SKOV3 cells, and the tumor growth was inhibited by over-expression of ST7L in vivo. Conclusion:ST7L could inhibit the proliferation and cell cycle of ovarian cells and tumor growth in vivo.
?
[1]Clarke-Pearson D L. Clinical practice. Screening for ovarian cancer[J]. N Engl J Med, 2009, 361(2): 170
[2]Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69
[3]Li S D, Zhang J R, Wang Y Q, et al. The role of microRNAs in ovarian cancer initiation and progression[J]. J Cell Mol Med, 2010, 14(9): 2240
[4]Kirikoshi H, Katoh M. Expression of ST7R (ST7-like, ST7L) in normal tissues and cancer[J]. Int J Oncol, 2002, 21(1): 193
[5]Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5
[6]Ozols R F, Bundy B N, Greer B E, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study[J]. J Clin Oncol, 2003, 21(17): 3194
[7]Mcguire W P, Hoskins W J, Brady M F, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer[J]. N Engl J Med, 1996, 334(1): 1
[8]Bristow R E, Tomacruz R S, Armstrong D K, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the Platinum era: a meta-analysis[J]. J Clin Oncol, 2002, 20(5): 1248
[9]Chester C, Dorigo O, Berek J S, et al. Immunotherapeutic approaches to ovarian cancer treatment[J]. Journal for Immunotherapy of Cancer, 2015, 3: 7
[10] Robertson D M. Screening for the early detection of ovarian cancer[J]. Womens Health (Lond Engl), 2009, 5(4): 347
[11]Saitoh T, Katoh M. Molecular cloning and characterization of mouse St7r (St7-like, St7l)[J]. Int J Mol Med, 2002, 10(1): 119
[12]Chen L C, Zhang A L, Li Y l, et al. MiR-24 regulates the proliferation and invasion of glioma by ST7L via β-catenin/Tcf-4 signaling[J]. Cancer Lett, 2013, 329(2): 174
[13]Kwak S Y, Yang J S, Kim B Y, et al. Ionizing radiation-inducible miR-494 promotes glioma cell invasion through EGFR stabilization by targeting p190B rhoGAP[J]. Biochim Biophys Acta, 2014, 1843(3): 508
[14]Katoh M. Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases[J]. Frontiers in cell and developmental biology, 2014, 2: 61
[15]Heo H S, Kim J H, Lee Y J, et al. Microarray profiling of genes differentially expressed during erythroid differentiation of murine erythroleukemia cells[J]. Mol Cells, 2005, 20(1): 57
[1]申彦,张新莹,师宜荃,等.Glut-1、HIF-1α及P53在卵巢癌中的表达及意义[J].天津医科大学学报,2013,19(05):383.
[2]范 丹,宋文静,张艳辉,等.PRRX1的表达对卵巢癌血管生成拟态形成及患者预后的影响[J].天津医科大学学报,2018,24(01):1.
FAN Dan,SONG Wen-jing,ZHANG Yan-hui,et al.Effect of PRRX1 expression on VM formation and prognosis in ovarian cancer[J].Journal of Tianjin Medical University,2018,24(05):1.
[3]徐灵灵,牛秀珑,张宏健,等.IL-17A促进卵巢癌顺铂耐药的体外机制探讨[J].天津医科大学学报,2018,24(03):192.
XU Ling-ling,NIU Xiu-long,ZHANG Hong-jian,et al.Study on the underlying mechanisms of IL-17A promoting the cisplatin-based resistance of ovarian cancer[J].Journal of Tianjin Medical University,2018,24(05):192.
[4]王雅蕾,王靖怡 综述,齐丽莎 审校.微环境在卵巢癌发生发展中的作用[J].天津医科大学学报,2020,26(03):288.
[5]李岩,牛秀珑,郁春艳,等.IL-17A可以促进卵巢癌的腹腔转移[J].天津医科大学学报,2020,26(06):518.
LI Yan,NIU Xiu-long,YU Chun-yan,et al.IL-17A promotes intraperitoneal metastasis of ovarian cancer[J].Journal of Tianjin Medical University,2020,26(05):518.
[6]李广宁 综述,曹文枫 审校.女性生殖系统双原发癌的研究进展[J].天津医科大学学报,2021,27(06):655.
[7]沈洋洋,牛秀珑,郁春艳,等.外源性IL-6 通过STAT3 通路促进卵巢癌细胞对顺铂
耐药[J].天津医科大学学报,2022,28(03):266.
SHEN Yang-yang,NIU Xiu-long,YU Chun-yan,et al.Exogenous IL-6 promotes cisplatin resistance of ovarian cancer through STAT3 pathway[J].Journal of Tianjin Medical University,2022,28(05):266.
[8]郑小燕,郁春艳,刘俊汝,等.IL-17A对卵巢癌进展的影响及机制研究[J].天津医科大学学报,2023,29(02):148.
ZHENG Xiao-yan,YU Chun-yan,LIU Jun-ru,et al.Effect and mechanism of IL-17A on the progression of ovarian cancer[J].Journal of Tianjin Medical University,2023,29(05):148.
基金项目 国家自然科学基金资助项目( 91029714; 31270818; 81572790);天津市自然科学基金资助项目(12JCZDJC25100)
作者简介 周闻(1982-),女,硕士在读,研究方向:病原生物学;通信作者:汤华,E-mail:htang2002@yahoo.com。
?